DK0527835T3 - Doseringsform til afgivelse af et anti-Parkinsonmiddel - Google Patents

Doseringsform til afgivelse af et anti-Parkinsonmiddel

Info

Publication number
DK0527835T3
DK0527835T3 DK91908910.2T DK91908910T DK0527835T3 DK 0527835 T3 DK0527835 T3 DK 0527835T3 DK 91908910 T DK91908910 T DK 91908910T DK 0527835 T3 DK0527835 T3 DK 0527835T3
Authority
DK
Denmark
Prior art keywords
parkinson
dosage form
delivery
agent
disease
Prior art date
Application number
DK91908910.2T
Other languages
English (en)
Inventor
Atul Devdatt Ayer
David Emil Edgren
Howard A Carpenter
Gurdish Kaur Bhatti
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of DK0527835T3 publication Critical patent/DK0527835T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
DK91908910.2T 1990-05-07 1991-05-01 Doseringsform til afgivelse af et anti-Parkinsonmiddel DK0527835T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/520,295 US5190763A (en) 1990-05-07 1990-05-07 Dosage form indicated for the management of abnormal posture, tremor and involuntary movement

Publications (1)

Publication Number Publication Date
DK0527835T3 true DK0527835T3 (da) 1995-04-18

Family

ID=24071988

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91908910.2T DK0527835T3 (da) 1990-05-07 1991-05-01 Doseringsform til afgivelse af et anti-Parkinsonmiddel

Country Status (17)

Country Link
US (1) US5190763A (da)
EP (1) EP0527835B1 (da)
JP (1) JP2634322B2 (da)
KR (1) KR0169146B1 (da)
AT (1) ATE113203T1 (da)
AU (1) AU641770B2 (da)
CA (1) CA2041579C (da)
DE (1) DE69104830T2 (da)
DK (1) DK0527835T3 (da)
ES (1) ES2067231T3 (da)
FI (1) FI925029A0 (da)
IE (1) IE62397B1 (da)
NO (1) NO924209L (da)
NZ (2) NZ238011A (da)
PT (1) PT97552B (da)
WO (1) WO1991016885A1 (da)
ZA (1) ZA913282B (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
SE9301112D0 (sv) * 1993-04-02 1993-04-02 Orion-Yhtymae Oy A new composition
US5369120A (en) * 1993-07-28 1994-11-29 Warner-Lambert Company Pharmaceutical composition of 7-((substituted)amino-8-((substituted)carbonyl)-(methylamino)-1-oxasp iro(4,5)decanes and L-dopa
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US20030056896A1 (en) * 1995-05-12 2003-03-27 Frank Jao Effective therapy for epilepsies
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6348208B1 (en) * 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
WO1996040085A2 (en) * 1995-06-07 1996-12-19 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
DE19626621A1 (de) * 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
US6623752B1 (en) 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
IL138290A0 (en) 1998-03-16 2001-10-31 Somerset Pharmaceuticals Inc Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
DE19855704C2 (de) * 1998-12-03 2002-08-01 Lothar Saiger Verwendung einer Wirkstoffkombination zur Behandlung der Parkinsonschen Krankheit
DE60038698T2 (de) * 1999-12-23 2009-05-07 Pfizer Products Inc., Groton Hydrogel-gesteuerte dosierungsform
JP2003518487A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク ヒドロゲル駆動型積層薬物製剤
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
US20030087814A1 (en) * 2001-11-05 2003-05-08 Seth Lederman Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
EP1496868A1 (en) * 2002-04-11 2005-01-19 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of carbidopa and levodopa
CA2523567A1 (en) * 2003-04-25 2004-11-11 Indevus Pharmaceuticals, Inc. Method for promoting uninterrupted sleep by administration of trospium chloride
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
AU2004270174B2 (en) 2003-08-29 2010-05-20 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
JP2005309912A (ja) * 2004-04-23 2005-11-04 Oki Data Corp 画像形成装置
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
CN101023056B (zh) * 2004-06-04 2011-05-25 克塞诺波特公司 左旋多巴前药、和组合物及其应用
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1845968A2 (en) 2004-11-24 2007-10-24 Neuromolecular Pharmaceuticals, Inc Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US8252331B2 (en) * 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
WO2006108055A1 (en) 2005-04-05 2006-10-12 Yale University Glutamate modulating agents in the treatment of mental disorders
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
DK1959948T3 (da) * 2005-12-05 2012-08-20 Xenoport Inc Levodopa prodrug-mesylat, sammensætninger deraf og anvendelser deraf
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
DE602006018529D1 (de) 2005-12-29 2011-01-05 Osmotica Kereskedelmi Es Szolgaltato Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
US9561188B2 (en) * 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
CL2007002574A1 (es) * 2006-09-08 2008-05-23 Drug Tech Corp Sa Organizada B Composicion farmaceutica oral que comprende levodopa en una dosis unitaria de alrededor de 100 hasta alrededor de 500 mg y un excipiente adecuado; y su uso para tratar parkinson.
US7709527B2 (en) * 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
WO2008079387A1 (en) * 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
PL2303330T5 (pl) * 2008-06-06 2021-10-25 Pharma Two B Ltd. Kompozycje farmaceutyczne do leczenia choroby Parkinsona
JP2012505885A (ja) * 2008-10-20 2012-03-08 ゼノポート，インコーポレーテッド レボドパエステルプロドラッグを合成する方法
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2010105093A2 (en) * 2009-03-12 2010-09-16 Delpor, Inc. Implantable device for long-term delivery of drugs
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
CN102883601A (zh) * 2009-12-02 2013-01-16 阿达玛斯医药公司 金刚烷胺组合物及其使用方法
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
AU2018320946A1 (en) 2017-08-24 2020-04-16 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4058122A (en) * 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4235236A (en) * 1979-02-12 1980-11-25 Alza Corporation Device for dispensing drug by combined diffusional and osmotic operations
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4743247A (en) * 1984-08-13 1988-05-10 Alza Corporation Process for manufacturing dosage form
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
US4716496A (en) * 1986-05-09 1987-12-29 Eaton Corporation Panel-mounted control station housing

Also Published As

Publication number Publication date
CA2041579A1 (en) 1991-11-08
AU641770B2 (en) 1993-09-30
NO924209D0 (no) 1992-11-02
ZA913282B (en) 1992-02-26
CA2041579C (en) 2003-09-30
KR0169146B1 (ko) 1999-01-15
FI925029A (fi) 1992-11-06
JP2634322B2 (ja) 1997-07-23
IE62397B1 (en) 1995-01-25
NZ238011A (en) 1995-12-21
NZ248491A (en) 1995-12-21
ES2067231T3 (es) 1995-03-16
JPH05506858A (ja) 1993-10-07
DE69104830D1 (de) 1994-12-01
KR930700076A (ko) 1993-03-13
IE911466A1 (en) 1991-11-20
PT97552B (pt) 1998-08-31
DE69104830T2 (de) 1995-03-02
US5190763A (en) 1993-03-02
ATE113203T1 (de) 1994-11-15
NO924209L (no) 1992-11-09
EP0527835B1 (en) 1994-10-26
AU7854391A (en) 1991-11-27
FI925029A0 (fi) 1992-11-06
PT97552A (pt) 1992-01-31
WO1991016885A1 (en) 1991-11-14
EP0527835A1 (en) 1993-02-24

Similar Documents

Publication Publication Date Title
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
MX171191B (es) Composiciones farmaceuticas de glipizida
NO306377B1 (no) Doseform for avgivelse av et medikament
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
ATE96308T1 (de) Dosierform fuer verabreichung in der humanmedizin.
ES2060941T3 (es) Uso de nicotina para la fabricacion de un estuche para el tratamiento de condiciones susceptibles de dicho tratamiento.
NO171145C (no) Fremgangsmaate for fremstilling av en fettemulsjon med et hydrofobt medikament
DE3872878T2 (de) Behandlung von diabetes durch kombinierte insulinformen.
DE69532810D1 (de) Intravenöse alendronatformulierungen
DK0738147T3 (da) Anvendelse af riluzol ved behandling af mitochondriesygdomme
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
SE8804640L (sv) Laekemedel omfattande cyklolinopeptide a
SE9101341D0 (sv) New medicinal use
IT1246050B (it) Impiego dell'eptastigmina nella terapia dell'ictus cerebrale.
SE9704451D0 (sv) New method and compositions for the treatment of autoimmune diseases
SE8903117D0 (sv) Laekemedel omfattande antamanid